Leonard Braden Michael's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Dec 29, 2022
- Accession no.
- 0001567619-22-022103
- Filed
- Dec 29, 2022
- Trade date
- Dec 28-29, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $80.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2022 | Common Stock | SSaleDisposed | −157 | $4.04 | −$634.28 | 269,843 | Direct | |
| Dec 29, 2022 | Common Stock | SSaleDisposed | −19,843 | $4.04F2 | −$80,165.72 | 250,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.